Iconovo AB (publ)

Stockholm Stock Exchange ICO.ST

Iconovo AB (publ) Interest Coverage Ratio for the year ending December 31, 2023: -88.78

Iconovo AB (publ) Interest Coverage Ratio is -88.78 for the year ending December 31, 2023, a 43.84% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Iconovo AB (publ) Interest Coverage Ratio for the year ending December 31, 2022 was -158.09.
Iconovo AB (publ) Interest Coverage Ratio for the year ending December 31, 2020 was -57,111.95, a -553.85% change year over year.
Iconovo AB (publ) Interest Coverage Ratio for the year ending December 31, 2019 was -8,734.72, a -946.65% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

Stockholm Stock Exchange: ICO.ST

Iconovo AB (publ)

CEO	Mr. Johan Waborg
IPO Date	April 6, 2018
Location	Sweden
Headquarters	Medicon Village
Employees	28
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Pollution Treatment Vaccines

Description

Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.

Key trends

Past 5 years